StreetInsider.com News Articles

Zai Lab to share first ZL-1503 clinical data at ACAAI 2026

Wed, 14 Oct 2026 07:01:53 -0400

Zai Lab Limited (NASDAQ: ZLAB) announced it will present data from the first clinical trial of ZL-1503, its internally developed IL-13/IL-31Rα bispecific antibody, at the American College of Allergy, Asthma & Immunology 2026 Annual Scientific Meeting in Phoenix, AZ, running November 12-16, 2026.

The data, drawn from a Phase 1/1b first-in-human study in healthy volunteers (NCT07235384), will be presented as a poster on November 13, 2026. The presentation will include pharmacokinetic data from single-dose administration, pharmacodynamic data on atopic dermatitis-related biomarkers across a range of doses, and initial safety and immunogenicity findings.

ZL-1503 is designed to simultaneously block both IL-13 and IL-31

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

Wed, 14 Oct 2026 07:00:00 -0400

- Findings from healthy volunteers in the Phase 1/1b trial will be shared at ACAAI 2026 Annual Scientific Meeting

- Previous non-clinical studies demonstrated the potential for ZL-1503 to provide rapid itch relief and reduce inflammation in atopic diseases

- Investor conference call and webcast to discuss data being presented at ACAAI and clinical trial plans scheduled for Friday, November 13 at 8:00 a.m. ET / 9:00 p.m. HKT

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company’s internally

Zai Lab to Present Data From First Clinical Trial Evaluating ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, for Atopic Diseases

Wed, 14 Oct 2026 07:00:00 -0400

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that data from the first clinical trial evaluating ZL-1503, the company’s internally

Zai Lab (ZLAB) Reiterated at Overweight by Cantor Fitzgerald

Tue, 06 Oct 2026 07:42:10 -0400

Cantor Fitzgerald analyst Li Watsek reiterated an Overweight rating and $37 price target on Zai Lab (NASDAQ: ZLAB).

The analyst commented, "Shares have rallied since 2Q earnings, and the recent withdrawal of I-DXd (B7-H3 ADC; Merck) puts Zai’s first-in-class DLL3 ADC, zocilurtatug, in pole position to potentially become the first ADC approved in 2L ES-SCLC. More importantly, ESMO data from initial 1L SCLC cohorts of zoci + atezolizumab with or without carboplatin could de-risk the 1L path, which has proven challenging for other ADCs. We think a 70–80% ORR and ~7-month mPFS are largely priced in; mPFS >8 months may be

Form 4 Zai Lab Ltd For: Oct 01 Filed by: Chen Yajing

Mon, 05 Oct 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20261005/27149477.html

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Tue, 29 Sep 2026 07:00:00 -0400

Poster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin
Data adds to body of evidence supporting zoci as a potential backbone antibody-drug conjugate in first-line combination regimens for ES-SCLC
Investor conference call and webcast to discuss data being presented at ESMO and zoci clinical trial plans scheduled for Friday, October 23 at 8:00 a.m. ET / 8:00 p.m. HKT

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that global data from a clinical trial evaluating zocilurtatug pelitecan (zoci, formerly ZL-1310) for

Zai Lab to Present First Global Data from Clinical Trial Evaluating Zocilurtatug Pelitecan (Zoci) As First-Line Treatment for Extensive-Stage Small Cell Lung Cancer (ES-SCLC)

Tue, 29 Sep 2026 07:00:00 -0400

Poster presentation at ESMO Congress 2026 will highlight findings from trial of zoci in combination with atezolizumab with and without carboplatin
Data adds to body of evidence supporting zoci as a potential backbone antibody-drug conjugate in first-line combination regimens for ES-SCLC
Investor conference call and webcast to discuss data being presented at ESMO and zoci clinical trial plans scheduled for Friday, October 23 at 8:00 a.m. ET / 8:00 p.m. HKT

Zai Lab (ZLAB) PT Raised to $36 at JPMorgan

Thu, 27 Aug 2026 08:33:56 -0400

JPMorgan analyst Anupam Rama raised the price target on Zai Lab (NASDAQ: ZLAB) to $36.00 (from $27.00) while maintaining a Overweight rating.

Form 144 Zai Lab Ltd Filed by: Smiley Joshua L

Thu, 20 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260820/26956450.html

Form 144 Zai Lab Ltd Filed by: Smiley Joshua L

Thu, 20 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260820/26956450.html

Form 144 Zai Lab Ltd Filed by: Smiley Joshua L

Thu, 20 Aug 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20260820/26956450.html

Form 144 Zai Lab Ltd Filed by: Chen Yajing

Wed, 19 Aug 2026 13:51:00 -0400

si-local-file:///var/storage/secattach/20260819/26949395.html

Form 144 Zai Lab Ltd Filed by: Chen Yajing

Wed, 19 Aug 2026 13:51:00 -0400

si-local-file:///var/storage/secattach/20260819/26949395.html

Form 144 Zai Lab Ltd Filed by: Chen Yajing

Wed, 19 Aug 2026 13:51:00 -0400

si-local-file:///var/storage/secattach/20260819/26949395.html

Zai Lab and argenx report Phase 3 trial win for myositis drug

Mon, 17 Aug 2026 06:00:59 -0400

Zai Lab (NASDAQ: ZLAB; HKEX: 9688) and argenx (Euronext & NASDAQ: ARGX) announced positive topline results from the Phase 3 ALKIVIA trial evaluating efgartigimod subcutaneous injection in adults with autoimmune myositis, according to a joint press release.

The study met its primary endpoint, with patients treated with efgartigimod showing a statistically significant 15.4-point greater improvement in mean Total Improvement Score (TIS) at Week 52 compared to placebo (47.95 vs. 32.56) in the combined immune-mediated necrotizing myopathy (IMNM) and dermatomyositis (DM) population (p=0.0011).